Therapeutic effects of acetylsalicylic acid in giant cell arteritis

Arthritis and Rheumatism

Volumn 46, Issue 2, 2002, Pages 457-466

  Weyand, Cornelia M ^a   Kaiser, Markus ^a   Yang, Hongyu ^a   Younge, Brian ^a   Goronzy, Jörg J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; CYTOKINE; DEXAMETHASONE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MESSENGER RNA; MONOKINE; PROSTAGLANDIN SYNTHASE; TRANSCRIPTION FACTOR AP 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY GRAFT; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ELECTROPHORETIC MOBILITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GIANT CELL ARTERITIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE CLONE; MONOCYTE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ASSAY; SCID MOUSE; T LYMPHOCYTE; TEMPORAL ARTERITIS; TEMPORAL ARTERY; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DEXAMETHASONE; DRUG SYNERGISM; GLUCOCORTICOIDS; HUMANS; INDOMETHACIN; INTERFERON TYPE II; MICE; MICE, SCID; MONOCYTES; NF-KAPPA B; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TEMPORAL ARTERIES; TEMPORAL ARTERITIS; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION, GENETIC;

EID: 0036169022     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10071     Document Type: Article

References (48)

1. Giant cell arteritis and Takayasu aortitis: Morphologic, pathogenetic and etiologic factors
2. Giant cell arteritis update
3. Giant cell arteritis: Pathogenesis
4. Arterial wall injury in giant cell arteritis
5. Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis
6. Formation of new vasa vasorum in vasculitis: Production of angiogenic cytokines by multinucleated giant cells
7. The Dunlop-Dottridge lecture: The pathogenesis of giant cell arteritis
8. Treatment of giant cell arteritis: Interleukin-6 as a biologic marker of disease activity
9. Laboratory investigations useful in the evaluation of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA)
10. Pathogenic principles in giant cell arteritis
11. Giant cell vasculitis is a T cell-dependent disease
12. Tissue-destructive macrophages in giant cell arteritis
13. Correlation of the topographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis
14. Polymyalgia rheumatica and giant cell arteritis
15. Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis-SCID chimeras
16. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis
17. Disease patterns and tissue cytokine profiles in giant cell arteritis
18. A multicenter placebo-controlled study of methotrexate (MTX) in giant cell arteritis (GCA)
19. Inhibition of NF-kappa B by sodium salicylate and aspirin
20. Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration
21. Salicylic acid and aspirin inhibit the activity of RSK2 kinase and repress RSK2-dependent transcription of cyclic AMP response element binding protein- and NF-kappa B-responsive genes
22. Antioxidant properties of aspirin: Characterization of the ability of aspirin to inhibit silica-induced lipid peroxidation, DNA damage, NF-kappaB activation, and TNF-alpha production
23. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis
24. Tissue cytokine patterns distinguish variants of rheumatoid synovitis
25. Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes
26. Functional disruption of the CD28 gene transcriptional initiator in senescent T cells
27. Cyclooxygenases: Structural, cellular, and molecular biology
28. Regulation of interferon-gamma gene expression
29. The nuclear factor YY1 suppresses the human gamma interferon promoter through two mechanisms: Inhibition of AP1 binding and activation of a silencer element
30. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
31. The mode of action of aspirin-like drugs: Effect on inducible nitric oxide synthase
32. Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappaB
33. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta
34. Inhibition of IkappaB kinase activity by sodium salicylate in vitro does not reflect its inhibitory mechanism in intact cells
35. The effect of sodium salicylate and aspirin on NF-kappa B
36. Inhibition of ultraviolet B-induced activator protein-1 (AP-1) activity by aspirin in AP-1-luciferase transgenic mice
37. Aspirin inhibits tumor cell invasiveness induced by Epstein-Barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression
38. Interaction of NF-kappaB and NFAT with the interferon-gamma promoter
39. Cell-type-specific activation of c-Jun N-terminal kinase by salicylates
40. Cross-talk between steroids and NF-kappa B: What language?
41. Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis
42. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids
43. Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell
44. Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors
45. Glucocorticoid-mediated repression of nuclear factor-kappaB-dependent transcription involves direct interference with transactivation
46. Methotrexate use in systemic vasculitis
47. Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 2: Inflammatory bowel disease, systemic vasculitis, and therapeutic toxicity
48. Combined treatment of giant-cell arteritis with methotrexate and prednisone: A randomized, double-blind, placebo-controlled trial